Tumor Cell-Derived Tgf-Beta At Tumor Center Independently Predicts Recurrence And Poor Survival In Oral Squamous Cell Carcinoma
Zhanyi Lu,Liang Ding,Haoyue Ding,Fengyao Hao,Yumei Pu,Yujia Wang,Sheng Chen,Yan Yang,Xingxing Zhao,Xiaofeng Huang,Lei Zhang,Zhiyong Wang,Qingang Hu,Yanhong Ni
DOI: https://doi.org/10.1111/jop.12888
2019-01-01
Abstract:Background Transforming growth factor-beta (TGF-beta) exerts its versatile function (oncogenic or tumor suppressive role) during the carcinogenesis in tumor microenvironment-dependent manner. Considering the tumor heterogeneity, spatial and temporal distribution of TGF-beta in oral squamous cell carcinoma (OSCC) remained to be elucidated. Methods Formalin-fixed, paraffin-embedded sections derived from 73 patients with OSCC were immunostained, revealing expression patterns of TGF-beta, both at the regions of tumor center (TC) and invasive tumor front (ITF). Results The TGF-beta levels on tumor cells, fibroblast-like cells (FLCs), and tumor-infiltrating lymphocytes (TILs) were comparable and showed to be cell-type-independent manner. Although TC regions harbored less positive staining of TGF-beta than ITF in tumor cells (TGF-beta(Tumor cell)) (89.0% vs 98.3%; P = 0.037), FLCs (TGF-beta(FLC)) (86.3% vs 96.6%; P = 0.043), and TILs (TGF-beta(TIL)) (83.6% vs 94.8%; P = 0.044), respectively, TGF-beta at TC regions, not at ITF, correlated to poor clinical outcomes. At TC regions, patients with high TGF-beta(Tumor cell) had high recurrence rate, and patients with high TGF-beta(TIL) showed inferior worst pattern of invasion. Of note, high TGF-beta(Tumor cell) at TC predicted shorter overall survival time, recurrence-free survival, and disease-free survival in patients with OSCC, whereas high TGF-beta(TIL) had no association with survival time. Cox regression analyses indicated that tumor cell-derived TGF-beta at TC was an independent risk factor for survival outcome in patients with OSCC. Conclusions Tumor cell-derived TGF-beta at TC regions, but not at ITF, could be a promising predictor for disease recurrence and poor prognosis of patients with OSCC.